Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1611 1637
This examiner grants 41% of resolved cases
Kyle A Purdy has managed 1000 resolved cases within Art Unit 1611 of Tech Center 1600. The examiner maintains an allowance rate of 41.0 percent. This baseline suggests a rigorous examination environment where a majority of applications do not reach allowance. Practitioners should prepare for a detailed prosecution process that requires robust technical arguments to overcome initial rejections in this art unit.
The data highlights a significant interview lift of 35.9 percent. This figure indicates that engaging in direct dialogue with the examiner may substantially improve the probability of securing a patent compared to written responses alone. The median days to allowance of 1519 reflects a lengthy prosecution timeline for successful applications. This duration suggests that applicants must be prepared for multiple rounds of office actions and potentially long wait times before reaching a final disposition.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17630843 | SYNERGISTIC MIXTURES FOR ARTHROPOD TOXICITY AND REPELLENCY | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18667002 | SKIN CARE SERUM COMPOSITION WITH NATURAL POLYMERS | Final Rejection | The Procter & Gamble Company |
| 17422859 | ANTIBACTERIAL COMPOSITION | Non-Final OA | LG CHEM, LTD. |
| 18703637 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | Non-Final OA | Ohio State Innovation Foundation |
| 18910515 | METHOD FOR COLORING HUMAN HAIR, COMPRISING THE APPLICATION OF A DYE HAVING AMINOSILICONE AND PIGMENT AND SUBSEQUENT IRRADIATION WITH UV/VIS RADIATION | Non-Final OA | Henkel AG & Co. KGaA |
| 18821462 | POLYANION COATED LIPID NANOPARTICLES AND METHODS OF USE THEREOF | Final Rejection | Massachusetts Institute of Technology |
| 18706889 | METHODS AND SYSTEMS FOR POINT-OF-CARE SYNTHESIS AND ADMINISTRATION OF PARTICLE-BASED THERAPEUTICS | Final Rejection | Verily Life Sciences LLC |
| 18592571 | ARTIFICIAL BONE IMPLANTS WITH NANOSCAFFOLD FOR SELF-TRIGGERED OSTEOGENIC DIFFERENTIATION OF STEM CELLS | Final Rejection | City University of Hong Kong |
| 18437576 | COMPOSITION FOR PHARMACEUTICAL TABLET, PHARMACEUTICAL TABLET USING THE SAME, AND MANUFACTURING METHOD THEREOF | Final Rejection | Mitsubishi Chemical Corporation |
| 18256655 | EXTRACT OF AT LEAST ONE PLANT OF THE CROCUS SATIVUS SPECIES COMPRISING A HIGH CONTENT OF CROCINS AND A LOW CONTENT OF SAFRANAL, AND COSMETIC USE THEREOF AS ANTIOXIDANT | Final Rejection | L'OREAL |
| 18396092 | Multicolored Oral Care Compositions and Methods for the Same | Final Rejection | Colgate-Palmolive Company |
| 17989516 | OIL-BASED INSECTICIDAL AND INSECT REPELLENT COMPOSITIONS | Non-Final OA | S. C. Johnson & Son, Inc. |
| 18806301 | SUPPORTED DRUG FORMULATIONS SHOWING CONTROLLED DRUG RELEASE, AND A METHOD FOR THEIR PREPARATION | Final Rejection | Morgan State University |
| 15551596 | COSMETIC PRODUCT COMPRISING A METAL CAN, AND THE CONTENTS OF SAME | Final Rejection | BEIERSDORF AG |
| 18832510 | A Composition Against Osmotic Stress | Final Rejection | ELC Management LLC |
| 18867060 | CONCENTRATED CONDITIONING COMPOSITIONS | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 18723765 | LIQUID COMPOSITION HAVING ENHANCED ANTIMICROBIAL ACTIVITY | Non-Final OA | Conopco Inc., d/b/a UNILEVER |
| 18591613 | COSMETIC AEROSOL PRODUCT | Final Rejection | Conopco, Inc., d/b/a UNILEVER |
| 17273857 | METHOD OF PRODUCING METAL NANOPARTICLES AND USES THEREOF | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 17767783 | COMPOSITIONS AND METHODS FOR DELIVERING NUCLEIC ACIDS TO CELLS | Non-Final OA | University of Maryland, Baltimore |
| 18272024 | LIPID NANOPARTICLES FOR TARGETED DELIVERY OF MRNA | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 19001161 | COSMETIC COMPOSITIONS COMPRISING A CYCLODEXTRIN HAVING A PARTICLE SIZE DISTRIBUTION | Non-Final OA | ROQUETTE FRERES |
| 18873090 | PHARMACEUTICAL COMPOSITION CONTAINING PIMITESPIB | Non-Final OA | TAIHO PHARMACEUTICAL CO., LTD. |
| 18490294 | ENHANCED ANTIMICROBIAL EFFICACY (SYNERGY) OF SILVER AND COPPER COMPOUNDS AND MEDICAL USE OF THEIR COMBINATIONS | Final Rejection | Nanordica Medical OÜ |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy